v3.26.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Income Statement [Abstract]        
Revenue $ 0 $ 70,000 $ 0 $ 70,000
Operating Expenses:        
Research and development 584,000 2,253,000 1,787,000 4,856,000
General and administrative 3,408,000 2,685,000 7,146,000 5,930,000
Total operating expenses 3,992,000 4,938,000 8,933,000 10,786,000
Operating loss (3,992,000) (4,868,000) (8,933,000) (10,716,000)
Other income (expense):        
Investment income, net 79,000 216,000 199,000 482,000
Other income (expense), net 984,000 (7,000) 929,000 (111,000)
Total other income 1,063,000 209,000 1,128,000 371,000
Net loss before benefit from income taxes and noncontrolling interests (2,929,000) (4,659,000) (7,805,000) (10,345,000)
Benefit from income taxes 0 0 (387,000) (962,000)
Net loss (2,929,000) (4,659,000) (7,418,000) (9,383,000)
Less - net income (loss) attributable to noncontrolling interests 0 0 0 0
Net loss attributable to Lisata Therapeutics, Inc. common stockholders $ (2,929,000) $ (4,659,000) $ (7,418,000) $ (9,383,000)
Basic and diluted loss per share        
Lisata Therapeutics, Inc. common stockholders- basic (in dollars per share) $ (0.32) $ (0.54) $ (0.82) $ (1.09)
Lisata Therapeutics, Inc. common stockholders - diluted (in dollars per share) $ (0.32) $ (0.54) $ (0.82) $ (1.09)
Weighted average common shares outstanding        
Basic shares (in shares) 9,106 8,605 9,056 8,604
Diluted shares (in shares) 9,106 8,605 9,056 8,604